Literature DB >> 1545406

Enzymatic basis for the transesterification of cocaine in the presence of ethanol: evidence for the participation of microsomal carboxylesterases.

C S Boyer1, D R Petersen.   

Abstract

The enzyme-mediated transesterification of the 2-carboxymethyl ester of cocaine to a 2-carboxyethyl ester in the presence of ethanol has been characterized in mice by using both in vitro and in vivo systems. Hepatic subcellular fractionation of mouse livers demonstrated that cocaine transesterification activity was detectable only in the microsomal fraction. The in vitro microsomal transesterification of cocaine in the presence of ethanol was inhibited by fluoride and diisopropylfluorophosphate but was insensitive to physostigmine, thereby indicating that the reaction is specifically catalyzed by a carboxylesterase. The transesterification activity of hepatic microsomes showed saturable Michaelis-Menten kinetics in the presence of increasing concentrations of ethanol or cocaine. Cocaine transesterification specific activity in isolated mouse kidney microsomes was approximately 1.5-fold greater than that measured in the liver, suggesting that the kidney could play a significant role in ethyl ester formation. Collectively, these observations demonstrate that the transesterification of cocaine in the presence of ethanol is probably the result of hepatic and possibly renal carboxylesterases localized in the endoplasmic reticulum. The ethyl ester of cocaine was also detected in the livers of mice coadministered ethanol (3.0 g/kg intragastrically) and cocaine (50 mg/kg i.p.). Cocaine and cocaine ethyl ester displayed similar pharmacokinetic profiles, with hepatic half-lives of approximately 6.5 min. Pretreatment of the mice with 100 mg/kg tri-o-tolylphosphate completely blocked in vivo formation of the ethyl ester metabolite, further supporting the involvement of B-esterases in the transesterification of cocaine to cocaine ethyl ester.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545406

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Testing for drugs of abuse. Pharmacokinetic considerations for cocaine in urine.

Authors:  J Osterloh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

3.  Identification and characterization of single chain anti-cocaine catalytic antibodies.

Authors:  Kathleen M McKenzie; Jenny M Mee; Claude J Rogers; Mark S Hixon; Gunnar F Kaufmann; Kim D Janda
Journal:  J Mol Biol       Date:  2006-11-03       Impact factor: 5.469

4.  Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies.

Authors:  J B Nobiletti; P I Jatlow; C W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

5.  Kinetic characterization of human butyrylcholinesterase mutants for the hydrolysis of cocaethylene.

Authors:  Shurong Hou; Max Zhan; Xirong Zheng; Chang-Guo Zhan; Fang Zheng
Journal:  Biochem J       Date:  2014-06-15       Impact factor: 3.857

6.  In vitro and in vivo trans-esterification of 1-[2(R)-(2-amino-2-methylpropionylamino)-3-(1H-indol-3-yl)propionyl]-3(S)-benzyl-piperidine-3-carboxylic acid ethyl ester and the effects of ethanol on its pharmacokinetics in rats.

Authors:  Zhesheng Chen; Arun K Agrawal; Ronald B Franklin; Kwan H Leung; Shuet-Hing Lee Chiu
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

7.  Cocaine and cocaethylene: effects on extracellular dopamine in the primate.

Authors:  R N Iyer; J B Nobiletti; P I Jatlow; C W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

8.  The role of tobacco smoking and illicit drug use in adolescent acute alcohol intoxication.

Authors:  Loes de Veld; Inge M Wolberink; Joris J van Hoof; Nico van der Lely
Journal:  BMC Pediatr       Date:  2021-05-17       Impact factor: 2.125

9.  Behavioral effects of ketamine and toxic interactions with psychostimulants.

Authors:  Tamaki Hayase; Yoshiko Yamamoto; Keiichi Yamamoto
Journal:  BMC Neurosci       Date:  2006-03-16       Impact factor: 3.288

10.  Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.

Authors:  Tamaki Hayase
Journal:  BMC Neurosci       Date:  2007-09-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.